| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0735-1097(87)80429-1 |
| P698 | PubMed publication ID | 2889758 |
| P2093 | author name string | M Hodges | |
| S Forman | |||
| M Herman | |||
| W Rogers | |||
| T Robertson | |||
| R Grose | |||
| B Chaitman | |||
| E Passamani | |||
| G Knatterud | |||
| M Terrin | |||
| P2860 | cites work | Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase | Q33447121 |
| Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation | Q39216239 | ||
| Efforts to Limit the Size of Myocardial Infarcts | Q40085674 | ||
| Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (2). | Q40117902 | ||
| Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (1). | Q40185037 | ||
| Acute coronary occlusion with impending infarction as an angiographic complication relieved by a guide-wire recanalization | Q40728507 | ||
| Announcement of protocol change in thrombolysis in myocardial infarction trial | Q45351559 | ||
| A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days | Q47207740 | ||
| The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. | Q53824140 | ||
| Thrombolytic therapy in patients with acute myocardial infarction. | Q53847340 | ||
| Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. | Q54135542 | ||
| High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. | Q54316988 | ||
| A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity | Q68923408 | ||
| Advantages and applications of the centerline method for characterizing regional ventricular function | Q69566733 | ||
| Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator | Q69859494 | ||
| Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands | Q69869028 | ||
| Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial | Q70040003 | ||
| Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial | Q70275606 | ||
| The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial | Q70331348 | ||
| Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator | Q70355905 | ||
| Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase | Q71019798 | ||
| Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction | Q71310542 | ||
| The use of single plane angiocardiograms for the calculation of left ventricular volume in man | Q72023273 | ||
| P433 | issue | 5 Suppl B | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angioplasty | Q539795 |
| thrombolysis | Q1931577 | ||
| plasminogen | Q107129060 | ||
| P304 | page(s) | 51B-64B | |
| P577 | publication date | 1987-11-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty | |
| P478 | volume | 10 |
| Q45327798 | A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction |
| Q33750028 | Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management |
| Q70040003 | Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial |
| Q39539827 | Emergency thrombolysis in acute myocardial infarction |
| Q39488446 | Experience with the use of tPA in the treatment of acute myocardial infarction |
| Q38020360 | Fibrinolytic therapy in coronary artery disease |
| Q39230901 | Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: a multicenter prospective assessment. Virginia Thrombolytic Study Group |
| Q33892518 | Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time: Implication for Costs of Management |
| Q35775273 | Improving the time to thrombolytic therapy for myocardial infarction by using a quality assurance audit |
| Q72659872 | Individual risk assessment for intracranial haemorrhage during thrombolytic therapy |
| Q41776364 | Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients |
| Q39605617 | New strategies in the development of thrombolytic agents |
| Q36255748 | Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians |
| Q37930063 | Reperfusion therapy in acute myocardial infarction: present status and controversy |
| Q70363554 | Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology |
| Q38614221 | Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris |
| Q38238333 | Thrombolytic therapy: a review of the literature on streptokinase and tissue plasminogen activator with implications for practice. |
| Q41199394 | Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators |
| Q38236911 | Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent |
| Q37483264 | Usefulness of serum unbound free fatty acid levels to predict death early in patients with ST-segment elevation myocardial infarction (from the Thrombolysis In Myocardial Infarction [TIMI] II trial). |
Search more.